BR112022007488A2 - Forma cristalina de base livre de um receptor c5a de componente do complemento - Google Patents

Forma cristalina de base livre de um receptor c5a de componente do complemento

Info

Publication number
BR112022007488A2
BR112022007488A2 BR112022007488A BR112022007488A BR112022007488A2 BR 112022007488 A2 BR112022007488 A2 BR 112022007488A2 BR 112022007488 A BR112022007488 A BR 112022007488A BR 112022007488 A BR112022007488 A BR 112022007488A BR 112022007488 A2 BR112022007488 A2 BR 112022007488A2
Authority
BR
Brazil
Prior art keywords
receptor
free
complement component
crystalline form
base crystalline
Prior art date
Application number
BR112022007488A
Other languages
English (en)
Portuguese (pt)
Inventor
Singh Rajinder
Yau Kwok
Zeng Yibin
Zhang Penglie
M Lui Rebecca
Krasinski Antoni
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of BR112022007488A2 publication Critical patent/BR112022007488A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022007488A 2019-11-08 2020-11-06 Forma cristalina de base livre de um receptor c5a de componente do complemento BR112022007488A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932652P 2019-11-08 2019-11-08
PCT/US2020/059287 WO2021092292A1 (en) 2019-11-08 2020-11-06 FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR

Publications (1)

Publication Number Publication Date
BR112022007488A2 true BR112022007488A2 (pt) 2022-07-12

Family

ID=75846182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007488A BR112022007488A2 (pt) 2019-11-08 2020-11-06 Forma cristalina de base livre de um receptor c5a de componente do complemento

Country Status (13)

Country Link
US (3) US11026935B2 (https=)
EP (1) EP4054577A4 (https=)
JP (1) JP2022554019A (https=)
KR (1) KR20220098179A (https=)
CN (1) CN114641289A (https=)
AU (1) AU2020378061A1 (https=)
BR (1) BR112022007488A2 (https=)
CA (1) CA3155596A1 (https=)
CL (1) CL2022001173A1 (https=)
IL (1) IL292317A (https=)
MX (1) MX2022005403A (https=)
WO (1) WO2021092292A1 (https=)
ZA (1) ZA202305622B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114867473A (zh) 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor
JP2022554019A (ja) * 2019-11-08 2022-12-27 ケモセントリックス，インコーポレイティド 補体成分Ｃ５ａ受容体の遊離塩基結晶形態
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
JP7839157B2 (ja) * 2020-10-28 2026-04-01 ケモセントリックス， インコーポレイテッド 化膿性汗腺炎を処置する方法
EP4137133A1 (en) 2021-08-19 2023-02-22 Sandoz AG Crystalline form of avacopan
WO2022263263A1 (en) 2021-06-16 2022-12-22 Sandoz Ag Crystalline form of avacopan
US20260027049A1 (en) 2024-07-23 2026-01-29 Amgen Inc. Avacopan formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4996467B2 (ja) * 2004-09-27 2012-08-08 アカディア ファーマシューティカルズ インコーポレイテッド Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
CN114867473A (zh) * 2019-11-08 2022-08-05 凯莫森特里克斯股份有限公司 补体成分c5a受体的盐形式
JP2022554019A (ja) * 2019-11-08 2022-12-27 ケモセントリックス，インコーポレイティド 補体成分Ｃ５ａ受容体の遊離塩基結晶形態
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途

Also Published As

Publication number Publication date
WO2021092292A1 (en) 2021-05-14
US20210137907A1 (en) 2021-05-13
EP4054577A1 (en) 2022-09-14
AU2020378061A1 (en) 2022-05-26
US20230381167A1 (en) 2023-11-30
JP2022554019A (ja) 2022-12-27
IL292317A (en) 2022-06-01
US11026935B2 (en) 2021-06-08
CL2022001173A1 (es) 2023-02-10
EP4054577A4 (en) 2023-11-29
MX2022005403A (es) 2022-05-24
US20220096453A1 (en) 2022-03-31
ZA202305622B (en) 2024-01-31
CN114641289A (zh) 2022-06-17
KR20220098179A (ko) 2022-07-11
CA3155596A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
BR112022007488A2 (pt) Forma cristalina de base livre de um receptor c5a de componente do complemento
BR112022007489A2 (pt) Forma amorfa de um receptor c5a de componente do complemento
JOP20220131A1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـ dgkalpha من أجل تنشيط المناعة
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
BR112018016671A2 (pt) sulfonilureias e compostos relacionados e uso do mesmo
PE20181016A1 (es) Compuestos antivirales de fosfodiamida de ester de beta aminoacido
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MX2018010983A (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
CU23616B7 (es) Forma cristalina gamma del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
BR112022008183A2 (pt) Formas de sal de um receptor de c5a de componente do complemento
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
SA521421262B1 (ar) مشتق أمين جديد حلقي غير متجانس وتركيبة صيدلانية تشتمل عليه
MX2019012967A (es) Cristal de base libre de derivados benzofurano y metodo de preparacion.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12017501397A1 (en) (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
EA200901474A1 (ru) Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
BR112021002565A8 (pt) Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MY195340A (en) Compositions for Preventing or Treating Dry Eye

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.